Role of surgery for pancreatic ductal adenocarcinoma in the era of multidisciplinary treatment

HIGHLIGHTS

• who: Kosei Takagi and colleagues from the DepartmentOkayama University and Pharmaceutical Sciences, Okayama, Japan have published the paper: Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment, in the Journal: (JOURNAL) of 30/Dec/2022
• future: Research is required even though MIPR on PDAC might be safe and feasible.

SUMMARY

There have been remarkable improvements in multidisciplinary treatment for PDAC; however, the prognosis for this disease remains poor, with a 5-year overall survival rate of approximately 10%. Despite the current developments of multidisciplinary treatment for PDAC . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.